Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

Overview of attention for article published in Frontiers in oncology, February 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 6 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 32 Dimensions

Readers on

mendeley: 41 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

MPN, 06 Dec 2021

Therapeutic cancer vaccination with peptide vaccines derived from mutant CALR with montanide as an adjuvant, is safe and…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.